• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

潜在的预后生物标志物丝氨酸蛋白酶抑制剂A12（SERPINA12）：对肝细胞癌的影响

Potential prognostic biomarker SERPINA12: implications for hepatocellular carcinoma.

作者信息

Yang Huan, Kong Panpan, Hou Songyu, Dong Xiaogang, Abula Imamumaimaitijiang, Yan Dong

机构信息

The Department of Hepatopancreatobiliary Surgery, The Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, 830011, Xinjiang, China.

The Department of Daily Surgery, The Affiliated Tumor Hospital of Xinjiang Medical University, UrumqiXinjiang, 830011, China.

出版信息

Clin Transl Oncol. 2025 Apr;27(4):1597-1611. doi: 10.1007/s12094-024-03689-w. Epub 2024 Sep 5.

DOI:10.1007/s12094-024-03689-w
PMID:39235554
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12000224/
Abstract

BACKGROUND

Hepatocellular carcinoma (HCC) remains one of the most prevalent malignant tumors, exhibiting a high morbidity and mortality rate. The mechanism of its occurrence and development requires further study. The objective of this study was to investigate the role of SERPINA12 in the diagnosis, prognosis prediction and biological function within HCC.

METHODS

The Cancer Genome Atlas (TCGA) data were employed to analyze the relationship between clinical features and SERPINA12 expression in HCC. Kaplan-Meier curves were utilized to analyze the correlation between SERPINA12 expression and prognosis in HCC. The function of SERPINA12 was determined by enrichment analysis, and the relationship between SERPINA12 expression and immune cell infiltration was investigated. The expression of SERPINA12 was examined in 75 patients with HCC using RT-qPCR and immunohistochemistry, and survival analysis was performed.

RESULTS

The expression of SERPINA12 from TCGA database was found to be significantly higher in HCC tissues than in normal tissues and carried a poor prognosis. ROC curve demonstrated the diagnostic potential of SERPINA12 for HCC. The multivariate Cox regression analysis showed that pathologic T stage, tumor status, and SERPINA12 expression were independently associated with patient survival. The SERPINA12 expression was found to correlate with immune cell infiltration. Our RT-qPCR and immunohistochemical analysis revealed high expression of SERPINA12 in tumor tissues. Survival analysis indicated its association with poor prognosis.

CONCLUSION

SERPINA12 is a promising biomarker for diagnosis and prognosis, and it is associated with immune cell infiltration.

摘要

背景

肝细胞癌（HCC）仍然是最常见的恶性肿瘤之一，发病率和死亡率都很高。其发生和发展机制仍需进一步研究。本研究的目的是探讨丝氨酸蛋白酶抑制剂A12（SERPINA12）在HCC诊断、预后预测及生物学功能方面的作用。

方法

利用癌症基因组图谱（TCGA）数据，分析HCC临床特征与SERPINA12表达之间的关系。采用Kaplan-Meier曲线分析SERPINA12表达与HCC预后的相关性。通过富集分析确定SERPINA12的功能，并研究SERPINA12表达与免疫细胞浸润之间的关系。采用逆转录定量聚合酶链反应（RT-qPCR）和免疫组织化学方法检测75例HCC患者中SERPINA12的表达，并进行生存分析。

结果

发现TCGA数据库中HCC组织中SERPINA12的表达明显高于正常组织，且预后较差。ROC曲线显示SERPINA12对HCC具有诊断潜力。多因素Cox回归分析表明，病理T分期、肿瘤状态和SERPINA12表达与患者生存独立相关。发现SERPINA12表达与免疫细胞浸润相关。我们的RT-qPCR和免疫组织化学分析显示肿瘤组织中SERPINA12高表达。生存分析表明其与预后不良有关。

结论

SERPINA12是一种有前景的诊断和预后生物标志物，且与免疫细胞浸润有关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/6c73d6b078fe/12094_2024_3689_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/cb3f6492fe2b/12094_2024_3689_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/cd103fa253fa/12094_2024_3689_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/c37b63dfaf85/12094_2024_3689_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/407fe7bb94fb/12094_2024_3689_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/fa217cf1a0ce/12094_2024_3689_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/0a25f154430b/12094_2024_3689_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/087aa1164ae0/12094_2024_3689_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/4f51a75db9a5/12094_2024_3689_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/490e26d684e1/12094_2024_3689_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/6c73d6b078fe/12094_2024_3689_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/cb3f6492fe2b/12094_2024_3689_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/cd103fa253fa/12094_2024_3689_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/c37b63dfaf85/12094_2024_3689_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/407fe7bb94fb/12094_2024_3689_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/fa217cf1a0ce/12094_2024_3689_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/0a25f154430b/12094_2024_3689_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/087aa1164ae0/12094_2024_3689_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/4f51a75db9a5/12094_2024_3689_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/490e26d684e1/12094_2024_3689_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ae8d/12000224/6c73d6b078fe/12094_2024_3689_Fig10_HTML.jpg

相似文献

1
Potential prognostic biomarker SERPINA12: implications for hepatocellular carcinoma.潜在的预后生物标志物丝氨酸蛋白酶抑制剂A12（SERPINA12）：对肝细胞癌的影响
Clin Transl Oncol. 2025 Apr;27(4):1597-1611. doi: 10.1007/s12094-024-03689-w. Epub 2024 Sep 5.
2
High expression of SMPD4 promotes liver cancer and is associated with poor prognosis.鞘磷脂磷酸二酯酶4（SMPD4）的高表达促进肝癌发生并与不良预后相关。
BMC Res Notes. 2025 Apr 10;18(1):159. doi: 10.1186/s13104-025-07212-4.
3
Upregulation of FEN1 Is Associated with the Tumor Progression and Prognosis of Hepatocellular Carcinoma.FEN1 的上调与肝细胞癌的肿瘤进展和预后相关。
Dis Markers. 2020 Jan 13;2020:2514090. doi: 10.1155/2020/2514090. eCollection 2020.
4
Overexpression of EWSR1 (Ewing sarcoma breakpoint region 1/EWS RNA binding protein 1) predicts poor survival in patients with hepatocellular carcinoma.EWSR1（尤因肉瘤断点区 1/EWS RNA 结合蛋白 1）的过表达预示着肝细胞癌患者的生存不良。
Bioengineered. 2021 Dec;12(1):7941-7949. doi: 10.1080/21655979.2021.1982844.
5
The diagnostic and prognostic value of H2AFY in hepatocellular carcinoma.H2AFY 在肝细胞癌中的诊断和预后价值。
BMC Cancer. 2021 Apr 15;21(1):418. doi: 10.1186/s12885-021-08161-4.
6
ARIH2 serves as a potential prognostic biomarker for hepatocellular carcinoma associated with immune infiltration and ferroptosis.ARIH2作为与免疫浸润和铁死亡相关的肝细胞癌的潜在预后生物标志物。
Front Immunol. 2025 Apr 7;16:1548691. doi: 10.3389/fimmu.2025.1548691. eCollection 2025.
7
High expression of HM13 correlates with poor prognosis in hepatocellular carcinoma.HM13 的高表达与肝癌的预后不良相关。
J Mol Histol. 2024 Oct;55(5):927-936. doi: 10.1007/s10735-024-10241-1. Epub 2024 Aug 19.
8
Construction and validation of a three-microRNA signature as prognostic biomarker in patients with hepatocellular carcinoma.构建并验证三 miRNA 标志物作为肝癌患者的预后生物标志物。
Int J Med Sci. 2021 Jan 1;18(4):984-999. doi: 10.7150/ijms.49126. eCollection 2021.
9
Diagnostic and prognostic value of lncRNA cancer susceptibility candidate 9 in hepatocellular carcinoma.长链非编码 RNA 癌症易感性候选物 9 在肝细胞癌中的诊断和预后价值。
World J Gastroenterol. 2019 Dec 28;25(48):6902-6915. doi: 10.3748/wjg.v25.i48.6902.
10
To construct and validate a risk score model of angiogenesis-related genes to predict the prognosis of hepatocellular carcinoma.构建并验证一个血管生成相关基因的风险评分模型，以预测肝细胞癌的预后。
Sci Rep. 2025 Feb 7;15(1):4660. doi: 10.1038/s41598-025-87459-w.

引用本文的文献

1
ADME gene-driven prognostic model for bladder cancer: a breakthrough in predicting survival and personalized treatment.膀胱癌的ADME基因驱动预后模型：预测生存和个性化治疗的一项突破。
Hereditas. 2025 Mar 19;162(1):42. doi: 10.1186/s41065-025-00409-4.

本文引用的文献

1
A large-scale proteomics resource of circulating extracellular vesicles for biomarker discovery in pancreatic cancer.用于胰腺癌生物标志物发现的循环细胞外囊泡的大规模蛋白质组学资源
Elife. 2024 Dec 18;12:RP87369. doi: 10.7554/eLife.87369.
2
Hepatocellular carcinoma: molecular mechanism, targeted therapy, and biomarkers.肝细胞癌：分子机制、靶向治疗和生物标志物。
Cancer Metastasis Rev. 2023 Sep;42(3):629-652. doi: 10.1007/s10555-023-10084-4. Epub 2023 Feb 2.
3
Evaluation of Tissue Expression of Vaspin and Serum Vaspin Concentration as a Prognostic and Risk Factor in Endometrial Cancer.
评估 Vaspin 在子宫内膜癌中的组织表达及其作为预后和风险因素的血清浓度。
Cells. 2022 Oct 11;11(20):3196. doi: 10.3390/cells11203196.
4
Global burden of primary liver cancer in 2020 and predictions to 2040.2020 年全球原发性肝癌负担及 2040 年预测。
J Hepatol. 2022 Dec;77(6):1598-1606. doi: 10.1016/j.jhep.2022.08.021. Epub 2022 Oct 5.
5
The cell cycle, cancer development and therapy.细胞周期、癌症发生和治疗。
Mol Biol Rep. 2022 Nov;49(11):10875-10883. doi: 10.1007/s11033-022-07788-1. Epub 2022 Aug 5.
6
Time-keeping and decision-making in the cell cycle.细胞周期中的时间调控与决策制定
Interface Focus. 2022 Jun 10;12(4):20210075. doi: 10.1098/rsfs.2021.0075. eCollection 2022 Aug 6.
7
ANKFN1 plays both protumorigenic and metastatic roles in hepatocellular carcinoma.ANKFN1 在肝细胞癌中发挥促肿瘤发生和转移的作用。
Oncogene. 2022 Jul;41(29):3680-3693. doi: 10.1038/s41388-022-02380-0. Epub 2022 Jun 21.
8
Emerging Therapies for Hepatocellular Carcinoma (HCC).肝细胞癌（HCC）的新兴疗法
Cancers (Basel). 2022 Jun 4;14(11):2798. doi: 10.3390/cancers14112798.
9
The burden of primary liver cancer caused by specific etiologies from 1990 to 2019 at the global, regional, and national levels.2019 年全球、区域和国家层面由特定病因导致的原发性肝癌负担。
Cancer Med. 2022 Mar;11(5):1357-1370. doi: 10.1002/cam4.4530. Epub 2022 Jan 6.
10
Comparison of liver cancer incidence and survival by subtypes across seven high-income countries.七种高收入国家肝癌发病率和亚型生存情况比较。
Int J Cancer. 2021 Dec 15;149(12):2020-2031. doi: 10.1002/ijc.33767. Epub 2021 Sep 14.